<PAGE>
                                                                      EXHIBIT 99

REPORT OF INDEPENDENT ACCOUNTANTS

To the Venturers of Genzyme Ventures II:

    In our opinion, the accompanying balance sheets and the related statements
of operations, of changes in venturers' capital (deficit) and of cash flows
present fairly, in all material respects, the financial position of Genzyme
Ventures II (the "Joint Venture") at December 31, 1999 and 1998, and the results
of its operations and its cash flows for each of the three years in the period
ended December 31, 1999, in conformity with accounting principles generally
accepted in the United States. These financial statements are the responsibility
of the Joint Ventures' management; our responsibility is to express an opinion
on these financial statements based on our audits. We conducted our audits of
these statements in accordance with auditing standards generally accepted in the
United States, which require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements, assessing the
accounting principles used and significant estimates made by management, and
evaluating the overall financial statement presentation. We believe that our
audits provide a reasonable basis for the opinion expressed above.

/s/ PRICEWATERHOUSECOOPERS LLP

Boston, Massachusetts
February 23, 2000
<PAGE>
                              GENZYME VENTURES II

                            STATEMENTS OF OPERATIONS

<TABLE>
<CAPTION>
                                                                FOR THE YEARS ENDED DECEMBER 31,
                                                              ------------------------------------
                                                                1999          1998          1997
                                                              --------      --------      --------
                                                                     (AMOUNTS IN THOUSANDS)
<S>                                                           <C>           <C>           <C>
Net product sales...........................................   $6,810       $ 5,598       $ 3,210
Operating costs and expenses:
  Cost of products sold.....................................   (2,256)       (2,443)         (868)
  Selling and marketing expenses............................   (4,980)       (7,950)       (4,611)
                                                               ------       -------       -------
    Total operating costs and expenses......................   (7,236)      (10,393)       (5,479)
                                                               ------       -------       -------

Operating loss..............................................     (426)       (4,795)       (2,269)

Other income:
  Investment income.........................................        1            20            --
                                                               ------       -------       -------
    Total other income......................................        1            20            --
                                                               ------       -------       -------
Net loss....................................................   $ (425)      $(4,775)      $(2,269)
                                                               ======       =======       =======
</TABLE>

   The accompanying notes are an integral part of these financial statements.
<PAGE>
                              GENZYME VENTURES II

                                 BALANCE SHEETS

<TABLE>
<CAPTION>
                                                                 DECEMBER 31,
                                                              -------------------
                                                                1999       1998
                                                              --------   --------
                                                                  (AMOUNTS IN
                                                                  THOUSANDS)
<S>                                                           <C>        <C>
                                     ASSETS

Cash and cash equivalents...................................    $21        $20
                                                                ===        ===

                  LIABILITIES AND VENTURERS' CAPITAL (DEFICIT)

Accounts payable to Genzyme Corporation (Note C)............     --         --
Commitments and contingencies (Note D)......................     --         --

Venturers' capital:
  Genzyme...................................................     21         20
  Genzyme Development Partners, L.P.........................     --         --
Total Venturers' capital....................................     21         20
                                                                ---        ---

Total liabilities and Venturers' capital....................    $21        $20
                                                                ===        ===
</TABLE>

   The accompanying notes are an integral part of these financial statements.
<PAGE>
                              GENZYME VENTURES II

                            STATEMENTS OF CASH FLOWS

<TABLE>
<CAPTION>
                                                                FOR THE YEARS ENDED DECEMBER 31,
                                                              ------------------------------------
                                                                1999          1998          1997
                                                              --------      --------      --------
                                                                     (AMOUNTS IN THOUSANDS)
<S>                                                           <C>           <C>           <C>
Cash flows from operating activities:
  Net loss..................................................   $(425)       $(4,775)      $(2,269)
Cash flows from financing activities:
  Capital contributed by Genzyme............................     426          3,095         2,469
  Capital contributed by Genzyme Development Partners,
    L.P.....................................................      --             --         1,500
                                                               -----        -------       -------
Increase (decrease) in cash.................................       1         (1,680)        1,700
Cash at beginning of period.................................      20          1,700            --
                                                               -----        -------       -------
Cash at end of period.......................................   $  21        $    20       $ 1,700
                                                               =====        =======       =======
</TABLE>

Supplemental disclosure of non-cash transaction:

    Conversion of accounts payable to Genzyme to capital--Note D

   The accompanying notes are an integral part of these financial statements.
<PAGE>
                              GENZYME VENTURES II

             STATEMENTS OF CHANGES IN VENTURERS' CAPITAL (DEFICIT)

<TABLE>
<CAPTION>
                                                                         GENZYME
                                                                       DEVELOPMENT
                                                           GENZYME      PARTNERS,          TOTAL
                                                         CORPORATION      L.P.          VENTURERS'
                                                           CAPITAL       CAPITAL     CAPITAL (DEFICIT)
                                                         -----------   -----------   -----------------
                                                                    (AMOUNTS IN THOUSANDS)
<S>                                                      <C>           <C>           <C>
Balance at December 31, 1996...........................    $(2,279)       $   --          $(2,279)

Capital contributions..................................      4,748         1,500            6,248
Net loss...............................................     (1,361)         (908)          (2,269)
                                                           -------        ------          -------
  Balance at December 31, 1997.........................      1,108           592            1,700

Capital contribution...................................      3,095            --            3,095
Net loss...............................................     (4,183)         (592)          (4,775)
                                                           -------        ------          -------
  Balance at December 31, 1998.........................         20            --               20

Capital contribution...................................        426            --              426
Net loss...............................................       (425)           --             (425)
                                                           -------        ------          -------
  Balance at December 31, 1999.........................    $    21        $   --          $    21
                                                           =======        ======          =======
</TABLE>

   The accompanying notes are an integral part of these financial statements.
<PAGE>
                              GENZYME VENTURES II

                         NOTES TO FINANCIAL STATEMENTS

DESCRIPTION OF REFERENCES

    In these notes to the financial statements of Genzyme Ventures II we refer
to:

    - Genzyme Development Partners, L.P. as "GDP;"

    - Genzyme Corporation as "Genzyme;"

    - GDP and Genzyme together as "venturers;" and

    - Genzyme Ventures II as the "joint venture."

NOTE A. ORGANIZATION

    In September 1989, GDP and Genzyme formed the joint venture under the terms
and provisions of the Delaware Uniform Partnership Act for the purpose of
manufacturing and marketing GDP's surgical products (the "Sepra products") in
the United States and Canada for use in human clinical trials or human surgical
procedures, other than in ophthalmic surgery. The Sepra products are based on
hyaluronic acid and are intended to be used to limit the incidence and severity
of postoperative adhesions.

    GDP has contributed its technology and $1.7 million to the joint venture;
and Genzyme has contributed its agreement to manufacture and market the Sepra
products, to make non-interest bearing loans to the joint venture in the amount
of any working capital deficiency, to make capital contributions to the extent
deemed necessary by GDP and Genzyme in connection with the business of the joint
venture and to allow the use of such trademarks, tradenames and logos as GDP and
Genzyme shall determine to be necessary and advisable for manufacturing and
marketing the Sepra products within the United States and Canada. In
August 1996, Genzyme received marketing approval for GDP's first product, Sepra
Film-Registered Trademark- bioresorbable membrane, and commenced commercial
sales of this product in the United States on behalf of the joint venture on
August 17, 1996 (commencement of operations).

NOTE B. ACCOUNTING POLICIES

ACCOUNTING METHOD

    The financial statements of our joint venture have been prepared under the
accrual method of accounting in conformity with generally accepted accounting
principles.

USE OF ESTIMATES

    The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make certain estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reported
period. Actual results could differ from those estimates.

REVENUE RECOGNITION

    Revenues and corresponding cost of sales from product sales are recognized
when goods are shipped by Genzyme to the end customer and title has passed as
provided in the Amended and Restated Joint Venture Agreement (described in
Note C).

INVENTORY

    Genzyme manufactures the Sepra products on behalf of the joint venture. The
Sepra products are then sold to the joint venture at the time Genzyme sells the
Sepra products to the end customer. The
<PAGE>
                              GENZYME VENTURES II

                   NOTES TO FINANCIAL STATEMENTS (CONTINUED)

NOTE B. ACCOUNTING POLICIES (CONTINUED)
joint venture does not hold the inventory and, therefore, no inventory is
reflected on the joint venture's balance sheet.

INCOME TAXES

    The joint venture's financial statements do not include a provision for
income taxes. Taxes, if any, are the liability of GDP and Genzyme, as partners.

UNCERTAINTIES

    The joint venture is subject to risks common to companies in the
biotechnology industry, including but not limited to, development by its
competitors of new technological innovations, protection of proprietary
technology, health care cost containment initiatives, product liability, market
acceptance of the Sepra products and compliance with the government regulations,
including those of the U.S. Department of Health and Human Services and the FDA.
In addition, the joint venture is dependent upon Genzyme's ability to produce
and market the Sepra products.

NOTE C. JOINT VENTURE AGREEMENT BETWEEN GDP AND GENZYME

    In March 1997, GDP and Genzyme reached agreement concerning the operation of
and allocations of profits and losses from the joint venture. Under the terms of
these agreements, Genzyme purchases product from the joint venture for resale by
Genzyme as sole distributor for the joint venture. Genzyme purchases the
products from the joint venture at Genzyme's price to the end-user less a
distributor's discount (subject to a minimum price) and receives reimbursement
for certain costs incurred in connection with the market introduction of the
Sepra products. Genzyme holds the inventory of the Sepra products and sells it
to the joint venture upon sales to third parties. Genzyme is not entitled to
reimbursement for general and administrative services it provides to the joint
venture until the first year in which the joint venture generates more than
$25.0 million in revenues, at which time Genzyme will receive a quarterly
commission for general and administrative services in an amount equal to 10% of
the joint venture's gross revenues.

    Under the terms of the Amended and Restated Joint Venture Agreement, GDP
will receive the first $5.6 million in profits generated by the joint venture,
Genzyme will receive the next $8.4 million in profits and, thereafter, Genzyme
and GDP will receive a 60% and 40% share, respectively, in the profits of the
joint venture. The first $200,000 of the joint venture's losses are allocated to
GDP and thereafter losses are allocated 40% to GDP and 60% to Genzyme except to
the extent that any losses allocable to GDP would result in the allocation of
such loss to Genzyme Development Corporation II as the general partner of GDP as
a result of the GDP limited partners' capital account balance having been
previously reduced to zero. In such an event, 100% of the losses, in excess of
the first $200,000, are allocated to Genzyme. These financial statements reflect
the terms of the Amended and Restated Joint Venture Agreement.

    The venturers' losses for the years ending December 31, 1999, 1998 and 1997
are allocated pursuant to the terms of the Amended and Restated Joint Venture
Agreement, which is retroactive to August 17, 1996.
<PAGE>
                              GENZYME VENTURES II

                   NOTES TO FINANCIAL STATEMENTS (CONTINUED)

NOTE C. JOINT VENTURE AGREEMENT BETWEEN GDP AND GENZYME (CONTINUED)
    Allocation of joint venture losses is summarized as follows (amounts in
thousands):

<TABLE>
<CAPTION>
                                                     FOR THE YEARS ENDED DECEMBER 31,
                                                   ------------------------------------
                                                     1999          1998          1997
                                                   --------      --------      --------
<S>                                                <C>           <C>           <C>
Joint Venture net loss...........................   $(425)       $(4,775)      $(2,269)
                                                    =====        =======       =======
Losses allocated to GDP..........................   $  --        $  (592)      $  (908)
Losses allocated to Genzyme......................   $(425)       $(4,183)      $(1,361)
</TABLE>

NOTE D. JOINT VENTURE CAPITAL

    In 1997, Genzyme contributed $1.5 million of cash to GDP through its
wholly-owned subsidiary, Genzyme Development Corporation II, which also is the
general partner of GDP. GDP contributed $1.5 million in 1997 and $200,000 in
1996 to the joint venture and agreed to allow the use of such trademarks,
tradenames and logos as the venturers shall determine to be necessary and
advisable for manufacturing and marketing the Sepra products within the United
States and Canada.

    Genzyme funded the operating losses of the Joint Venture in 1999, 1998 and
1997 and intends to fund the operating losses of the joint venture in 2000.

    Genzyme converted its receivables from the joint venture of $0.4 million in
1999, $3.1 million in 1998 and $2.3 million in 1997 to capital.